Phio Pharmaceuticals Files 8-K
Ticker: PHIO · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1533040
| Field | Detail |
|---|---|
| Company | Phio Pharmaceuticals Corp. (PHIO) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, sec-filing, financials
TL;DR
Phio Pharma filed an 8-K on Jan 13, 2025, for other events and financials. Standard disclosure.
AI Summary
Phio Pharmaceuticals Corp. filed an 8-K on January 13, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not detail specific transactions or financial results but serves as a notification of these items to the SEC. The company's principal executive offices are located in Marlborough, Massachusetts.
Why It Matters
This 8-K filing indicates that Phio Pharmaceuticals Corp. is making required disclosures to the SEC regarding other events and financial statements, which is standard for public companies.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of 'Other Events' and 'Financial Statements and Exhibits' without any specific material events or changes mentioned.
Key Numbers
- 001-36304 — SEC File Number (Identifies the company's filing with the SEC.)
- 20250113 — Filing Date (The date the 8-K was filed with the SEC.)
Key Players & Entities
- Phio Pharmaceuticals Corp. (company) — Registrant
- January 13, 2025 (date) — Date of earliest event reported
- Marlborough, Massachusetts (location) — Address of principal executive offices
- 001-36304 (company) — SEC File Number
FAQ
What specific 'Other Events' are being reported by Phio Pharmaceuticals Corp. in this 8-K filing?
The filing does not specify the nature of the 'Other Events' beyond listing it as an item information category.
When was the earliest event reported in this 8-K filing?
The earliest event reported is January 13, 2025.
What is the principal executive office address for Phio Pharmaceuticals Corp.?
The principal executive offices are located at 11 Apex Drive, Suite 300A, PMB 2006, Marlborough, Massachusetts 01752.
What is the SEC file number for Phio Pharmaceuticals Corp.?
The SEC file number for Phio Pharmaceuticals Corp. is 001-36304.
Does this 8-K filing contain any information about recent financial performance or material agreements?
This filing lists 'Financial Statements and Exhibits' as an item, but the provided text does not detail specific financial performance or agreements.
Filing Stats: 485 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2025-01-13 10:55:47
Key Financial Figures
- $0.0001 — h registered: Common Stock, par value $0.0001 per share PHIO The Nasdaq Capital M
Filing Documents
- phio_8k.htm (8-K) — 26KB
- phio_ex9901.htm (EX-99.1) — 13KB
- image_001.jpg (GRAPHIC) — 2KB
- 0001683168-25-000274.txt ( ) — 216KB
- phio-20250113.xsd (EX-101.SCH) — 3KB
- phio-20250113_lab.xml (EX-101.LAB) — 33KB
- phio-20250113_pre.xml (EX-101.PRE) — 22KB
- phio_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On January 13, 2025, Phio Pharmaceuticals Corp. (the "Company") issued a press release announcing promising results of the second cohort from its ongoing clinical study of PH-762. These results are now available for the 4 patients who completed treatment in the 2nd cohort. Complete response (100% tumor clearance) is reported for 2 patients with cutaneous squamous cell carcinoma. Partial response (90% tumor clearance) is reported for 1 patient with cutaneous squamous cell carcinoma and 1 patient had stable disease, having not progressed. The full text of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Number Description 99.1 Press Release issued by the Company on January 13, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PHIO PHARMACEUTICALS CORP. Date: January 13, 2025 By: /s/ Robert Bitterman Robert Bitterman President & Chief Executive Officer 3